<DOC>
	<DOCNO>NCT01269229</DOCNO>
	<brief_summary>The purpose study increase resection rate primary cancer rectal short course radiotherapy without interrupt chemotherapy schedule period chemotherapy . The subject pathologically confirm unresectable ( impossible try Total mesorectal excision ) rectal cancer liver metastasis . This trial contribute save time decrease primary tumor rectal metastasis cancer whole body short course radiotherapy .</brief_summary>
	<brief_title>A Trial Neoadjuvant FOLFOX6 With Short Course Radiotherapy Patients With Unresectable Rectal Cancer Liver Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Subject pathologically confirm unresectable ( impossible try Total mesorectal excision ) rectal cancer liver metastasis . Over 18 year ECOG 01 Proper organ function ( hepatic transaminase : &lt; ULN ⅹ5 , Bilirubin : &lt; ULNⅹ2 , creatinine ( serum ) : &lt; ULNⅹ 1.5 , PLT &gt; 100,000Ul , ANC &gt; 1,500/Ul one target lesion ( standard RECIST 1.0 ) Who sign Informed consent form participate trial . Metastasis organ except liver ( No matter whether resection ) Chronic active hepatitis cirrhosis History treatment colorectal cancer Subject pregnant breast feeding Uncontrolled disease ( eg . infection , hypertension , heart failure , Myocardial Infarction within 6months ) Have use FOLFOX adjuvant therapy Have adjuvant therapy within 6months Uncontrolled peripheral nerve infection Alcoholic drug addict Subject currently enrol ≤30 day end clinical trial . History type cancer except resolve skin cancer cervical cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>